The global sepsis diagnostics market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%.
The demand is expected to grow due to the rising incidence of sepsis, a growing number of surgical procedures, high incidence of hospital-acquired infections, and increasing availability of a wide variety of sepsis diagnostic devices. The sepsis diagnostics industry is segmented on the technology, product, method, pathogen, test type, end-user, and region.
The blood culture segment accounted for the largest share of the sepsis diagnostics industry, by end-user, in 2019.
Based on end-users, the sepsis diagnostics market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. In 2019, blood culture accounted for the largest share of the market due to the increasing incidences of sepsis coupled with the growing adoption of blood culture techniques for the diagnosis of sepsis.
The blood culture media segment accounted for the largest share of the sepsis diagnostics market, by product, in 2019.
The market, by product, is segmented into blood culture media, assays & reagents, instruments, and software. In 2019, the blood culture media segment accounted for the largest share of the sepsis diagnostics industry due to the usage of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis across the globe.
North America accounted for the largest share of the sepsis diagnostics market in 2019.
North America accounted for the largest share of the global market in 2019, followed by Europe. This can primarily be attributed to the extensive availability of advanced sepsis diagnostic technologies, well-established distribution channels, and significant public awareness about the clinical benefits of diagnostic products in risk assessment for infectious diseases.
Some of the prominent players in the sepsis diagnostics market are bioMerieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), Roche Diagnostics (Switzerland), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), and CytoSorbents (US).
Key Topics Covered
2 Research Methodology
3 Executive Summary
4 Premium Insights 4.1 Sepsis Diagnostics: Market Overview 4.2 Sepsis Diagnostics Market, by Technology 4.3 Geographic Analysis: Sepsis Diagnostics Market, by Product and Region 4.4 APAC: Sepsis Diagnostics Market, by Country and End-user 4.5 Sepsis Diagnostics Market, by Pathogen 4.6 Geographic Snapshot of the Sepsis Diagnostics Market
5 Market Overview 5.1 Introduction 5.2 Market Dynamics 5.2.1 Drivers 22.214.171.124 High Incidence of Sepsis 126.96.36.199 Rising Incidence of Hospital-Acquired Infections 188.8.131.52 Growing Funding for Sepsis-Related Research 5.2.2 Restraints 184.108.40.206 Unfavorable Reimbursement Scenario 220.127.116.11 High Cost of Automated Diagnostic Devices 5.2.3 Opportunities 18.104.22.168 Development of Rapid Diagnostic/POC Techniques for Early Sepsis Diagnosis 22.214.171.124 Evolution of Novel Biomarkers for Sepsis Diagnosis 5.2.4 Challenges 126.96.36.199 Lack of Standard Protocols and Awareness 188.8.131.52 Shortage of Skilled Healthcare Professionals
6 Sepsis Diagnostics Market, by Technology 6.1 Introduction 6.2 Blood Culture 6.2.1 Blood Culture Holds the Largest Share of the Technology Market 6.3 Immunoassays 6.3.1 Product Development Efforts by Major Players Have Ensured Demand for Immunoassays 6.4 Molecular Diagnostics 6.4.1 Polymerase Chain Reaction 184.108.40.206 PCR Holds the Largest Share of the Molecular Diagnostics Market 6.4.2 Microarrays 220.127.116.11 Simultaneous Analysis Capabilities, Accuracy, and Rapidity Have Driven the Use of Microarrays 6.4.3 Peptide Nucleic Acid-Fluorescent in Situ Hybridization 18.104.22.168 PNA-Fish Kits Allow for the Rapid Diagnosis of BSIS 6.4.4 Syndromic Panel-Based Testing 22.214.171.124 High Costs and Accuracy Issues Have Affected Test Adoption 6.5 Flow Cytometry 6.5.1 Lack of Standardized Protocols is a Key Restraint in this Market Segment 6.6 Microfluidics 6.6.1 Growing Adoption of Advanced & Rapid Testing Will Favor Market Growth in this Segment 6.7 Biomarkers 6.7.1 Despite Potential, No Single Ideal Biomarker Has Been Identified for Sepsis Diagnostics
7 Sepsis Diagnostics Market, by Product 7.1 Introduction 7.2 Blood Culture Media 7.2.1 Blood Culture Media Dominate the Products Market 7.3 Assays & Reagents 7.3.1 Increasing Awareness Has Driven the Use of Assays & Reagents 7.4 Instruments 7.4.1 Market is Characterized by a Shift from Traditional & Manual Instruments to Automated Systems 7.5 Software 7.5.1 Rising Use of Automated Instruments Will Ensure Demand for Software
8 Sepsis Diagnostics Market, by Method 8.1 Introduction 8.2 Conventional Diagnostics 8.2.1 Conventional Diagnostics Holds Largest Market Share 8.3 Automated Diagnostics 8.3.1 Automated Diagnostics Segment to Grow at the Highest CAGR
9 Sepsis Diagnostics Market, by Pathogen 9.1 Introduction 9.2 Bacterial Sepsis 9.2.1 Gram-Negative Bacterial Sepsis 126.96.36.199 Gram-Negative Bacteria Cause ~50% of Sepsis Infections 9.2.2 Gram-Positive Bacterial Sepsis 188.8.131.52 Cases of Sepsis Caused by Gram-Positive Bacteria Have Risen in Recent Years 9.3 Fungal Sepsis 9.3.1 Fungemia is the Second-Biggest Cause of Bloodstream Infections 9.4 Other Pathogens
10 Sepsis Diagnostics Market, by Test Type 10.1 Introduction 10.2 Laboratory Tests 10.2.1 Laboratory Tests are the Most Common and Preferred Mode of Testing 10.3 Point-of-Care Tests 10.3.1 Rapidity and Convenience Have Driven Demand for POC Tests
11 Sepsis Diagnostics Market, by End-user 11.1 Introduction 11.2 Hospitals 11.2.1 Hospitals Hold the Largest Share of the Sepsis Diagnostics Market 11.3 Pathology & Reference Laboratories 11.3.1 Independent Laboratories Offer Affordability as Well as the Benefits of Bundled Services 11.4 Research Laboratories & Academic Institutes 11.4.1 Government Support and Rising Awareness Have Ensured Demand for Market Products in this Segment
12 Sepsis Diagnostics Market, by Region 12.1 Introduction 12.2 North America 12.2.1 US 184.108.40.206 US is the Largest Market for Sepsis Diagnostics 12.2.2 Canada 220.127.116.11 Growing Availability of Sepsis Diagnostic Products to Support Market Growth in Canada 12.3 Europe 12.3.1 Germany 18.104.22.168 Germany Accounted for the Largest Share of the European Market 12.3.2 France 22.214.171.124 High Incidence and Rising Awareness Have Supported the Demand for Sepsis Diagnostics in France 12.3.3 UK 126.96.36.199 Government Support and Rising Awareness are Key Drivers in the UK 12.3.4 Italy 188.8.131.52 Sluggish Growth in the Italian Healthcare Sector in the Last Few Years to Restrain the Market Growth 12.3.5 Spain 184.108.40.206 Rising Sepsis Incidence to Drive Market Growth in Spain 12.3.6 Rest of Europe 12.4 Asia-Pacific 12.4.1 Japan 220.127.116.11 Significant Growth in Pneumonia and Infectious Disease Incidence to Support Market Growth in Japan 12.4.2 China 18.104.22.168 Healthcare Infrastructure Improvements to Support Market Growth in China 12.4.3 India 22.214.171.124 Increasing Patient Population and Rising Number of Surgical Procedures are Key Growth Drivers in India 12.4.4 Australia 126.96.36.199 Increasing Number of Sepsis Treatment Procedures Indicates Growth Potential in the Australian Market 12.4.5 South Korea 188.8.131.52 Rising Healthcare Spending Supports Market Growth in South Korea 12.4.6 Rest of Asia-Pacific 12.5 Latin America 12.5.1 Brazil 184.108.40.206 Brazil Accounted for the Largest Share of the Latam Market 12.5.2 Mexico 220.127.116.11 Rising Medical Tourism to Support Market Growth in Mexico 12.5.3 Rest of Latin America 12.6 Middle East & Africa 12.6.1 High Consumption of Immune System-Suppressing Medications is Driving Sepsis Occurrence